Get the Stockscreener App
16.64
1.65%
0.27
Dyne Therapeutics Inc stock is traded at $16.64, with a volume of 3.56M.
It is up +1.65% in the last 24 hours and down -13.29% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$16.37
Open:
$16.41
24h Volume:
3.56M
Relative Volume:
0.96
Market Cap:
$3.11B
Revenue:
Net Income/Loss:
$-451.71M
P/E Ratio:
-5.1579
EPS:
-3.2261
Net Cash Flow:
$-462.19M
1W Performance:
+9.47%
1M Performance:
-13.29%
6M Performance:
-14.05%
1Y Performance:
+13.35%
1-Day Range:
$16.36
$17.31
1-Week Range:
$14.93
$17.31
52-Week Range:
$13.72
$27.30
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
16.64 | 3.11B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-26 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-26 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-26 | Initiated | TD Cowen | Buy |
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
At $16 a share, director Brian S. Posner buys 2,500 Dyne Therapeutics (DYN) shares. - Stock Titan
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 - Investing News Network
Certain Restricted Stock Units of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026. - marketscreener.com
Certain Stock Options of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026. - marketscreener.com
New Dyne hires receive stock tied to 278,100 shares - Stock Titan
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Dyne Therapeutics at Cantor conference: launch plans and pipeline expand By Investing.com - Investing.com Canada
Dyne Therapeutics at Cantor conference: launch plans and pipeline expand By Investing.com - Investing.com UK
(DYN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Baird Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Wall Street Slashes Dyne Therapeutics Targets After Novartis DM1 Trial Failure - finance.biggo.com
DYN Maintained by Morgan Stanley -- Price Target Lowered to $36 - GuruFocus
Dyne Therapeutics Shares Plummet After Novartis Phase 3 Trial Failure - Intellectia AI
Dyne Therapeutics CMO Kerr Douglas Sells 5,035 Shares Between $18.88 and $24.35 (NASDAQ: DYN) - Kalkine Media
DYN Downgraded by JP Morgan -- Price Target Lowered to $10.00 - GuruFocus
Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says - Moomoo
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Yahoo Finance
DYN Maintains Rating by RBC Capital -- Price Target Lowered to $30 - GuruFocus
Dyne downgraded at J.P. Morgan on Novartis setback (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics stock price target lowered to $30 by RBC Capital - Investing.com Canada
Dyne Therapeutics stock price target lowered to $30 by RBC Capital - Investing.com UK
Dyne Therapeutics falls 16% after Novartis DM1 trial failure raises doubts on RNA therapy success - Pluang
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN) - Seeking Alpha
RBC Cuts Price Target on Dyne Therapeutics to $30 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com Nigeria
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Stocktwits
Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com Australia
Dyne Therapeutics (DYN) officer plans $106K stock sale - Stock Titan
Dyne Therapeutics (Nasdaq: DYN) officer to sell 3,000 shares from RSUs - Stock Titan
Dyne Therapeutics (DYN) CCO’s tax sales leave 102,966 unvested RSUs - Stock Titan
Tax-driven stock sale by Dyne (DYN) medical chief - Stock Titan
Dyne Therapeutics (DYN) CEO sells shares to cover taxes - Stock Titan
Raymond James sets Dyne Therapeutics price targ... - Pluang
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling - Benzinga
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Yahoo Finance
Raymond James cuts Dyne Therapeutics price target on DM1 trial risk - Investing.com Nigeria
Raymond James cuts Dyne Therapeutics price target on DM1 trial risk - Investing.com Canada
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 at Upcoming Medical Meetings - Investing News Network
Morning Market Movers: FCUV, BNC, BIAF, DYN See Big Swings - rttnews.com
Dyne Therapeutics (DYN) Shares Plunge 28% After Novartis Phase I - GuruFocus
Dyne Therapeutics (DYN) Faces Market Pressure After Novartis DM1 - GuruFocus
Dyne Therapeutics (DYN) Faces Pressure After Novartis Trial Fail - GuruFocus
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings - Yahoo Finance
Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com Australia
Dyne Therapeutics stock faces pressure after rival drug fails trial - Investing.com
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed - Yahoo Finance
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dyne Therapeutics Inc Stock (DYN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cox John | CEO & President |
Sep 08 '26 |
Sale |
18.88 |
5,658 |
106,823 |
357,507 |
| Cox John | Officer |
Sep 08 '26 |
Proposed Sale |
18.88 |
5,658 |
106,844 |
0 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 08 '26 |
Sale |
18.88 |
185 |
3,493 |
152,897 |
| Kerr Douglas | Officer |
Sep 08 '26 |
Proposed Sale |
18.89 |
35 |
661 |
0 |
| Kerr Douglas | Chief Medical Officer |
Sep 08 '26 |
Sale |
18.88 |
1,290 |
24,355 |
162,564 |
| Kerr Douglas | Officer |
Sep 04 '26 |
Proposed Sale |
24.35 |
5,000 |
121,745 |
0 |
| Kerr Douglas | Chief Medical Officer |
Sep 04 '26 |
Sale |
24.35 |
3,745 |
91,191 |
163,854 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 04 '26 |
Sale |
24.35 |
900 |
21,915 |
153,082 |
| Atlas Venture Opportunity Fund | Shareholder |
Aug 14 '26 |
Proposed Sale |
25.96 |
322,465 |
8,371,191 |
0 |
| Rhodes Jason P | Director |
Aug 14 '26 |
Sale |
25.00 |
2,160,516 |
54,012,900 |
428,946 |
0.86%
2.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):